The FDA granted Sanofi (SNY) US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Cautious Hold Rating on Sanofi Due to Safety Concerns and Limited Growth Prospects for Qfitlia
- Alnylam announces FDA approval of Qfitlia for treatment of hemophilia A or B
- FDA approves Sanofi treatment for hemophilia A or B
- Biotech Alert: Searches spiking for these stocks today
- Regeneron (NASDAQ:REGN) and Sanofi Get Japan Green Light for Smokers’ Lung Disease Treatment